{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:35:52Z","timestamp":1774352152817,"version":"3.50.1"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2021MH337"],"award-info":[{"award-number":["ZR2021MH337"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014103","name":"Key Technology Research and Development Program of Shandong","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Recent studies have reported that similar to other IgG4 autoimmune diseases, such as muscle-specific kinase antibody-associated myasthenia gravis, most anti-neurofascin-155 (anti-NF155) nodopathies respond well to rituximab treatment, regardless of the dosage. However, there are still a few patients for which rituximab is ineffective for unknown reasons. Currently, there are no studies on the mechanism of ineffective treatment with rituximab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A 33-year-old Chinese man presenting with numbness, tremor, and muscle weakness for 4 years was recruited for this study. Anti-NF155 antibodies were identified by cell-based assay and confirmed by immunofluorescence assay on teased fibers. The anti-NF155 immunoglobulin (IgG) subclasses were also detected by immunofluorescence assay. Anti-rituximab antibodies (ARAs) were quantitatively analyzed using enzyme-linked immunosorbent assay (ELISA), and peripheral B cell counts were determined by flow cytometry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The patient exhibited anti-NF155 IgG4-antibody positivity. After the first round of rituximab infusion, the patient showed stratified outcomes with improvements in numbness, muscle weakness and ambulation. However, after three rounds of rituximab infusion, the patient\u2019s symptoms deteriorated, and the numbness, tremor and muscle weakness returned. No obvious improvement was found after plasma exchange and another round of rituximab treatment. 14 days after the last treatment with rituximab, ARAs were detected. And the titers gradually decreased on day 28 and 60 but remained higher than normal. Peripheral CD19<jats:sup>+<\/jats:sup> B cell counts were less than 1% within the 2-month period following the final rituximab administration.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, ARAs presented in a patient with anti-NF155 nodopathy undergoing rituximab treatment and showed an unfavorable impact on rituximab efficacy. This is the first case to report the occurrence of ARAs in patients with anti-NF155 antibodies. We suggest that ARAs should be tested early during the initial intervention, especially in patients who respond poorly to rituximab treatment. In addition, we believe it is necessary to investigate the association between ARAs and B cell counts, their effect on clinical efficacy, and their potential adverse reactions in a larger cohort of patients with anti-NF155 nodopathy.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2023.1121705","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T04:33:40Z","timestamp":1679978020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":14,"title":["Anti-rituximab antibodies in patients with refractory autoimmune nodopathy with anti-neurofascin-155 antibody"],"prefix":"10.3389","volume":"14","author":[{"given":"Yunfei","family":"Bai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanzhu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral nerve society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force-second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2017-317192","article-title":"Autoimmune nodo-paranodopathies of peripheral nerve: The concept is gaining ground","volume":"89","author":"Uncini","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001107","article-title":"Autoimmune nodopathies, an emerging diagnostic category","volume":"35","author":"Martin-Aguilar","year":"2022","journal-title":"Curr Opin Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000149","article-title":"Rituximab in treatment-resistant cidp with antibodies against paranodal proteins","volume":"2","author":"Querol","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577280","article-title":"Efficacy of low dose rituximab in treatment-resistant cidp with antibodies against nf-155","volume":"345","author":"Jiao","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/acn3.51550","article-title":"Clinical and diagnostic features of anti-Neurofascin-155 antibody-positive neuropathy in han Chinese","volume":"9","author":"Wang","year":"2022","journal-title":"Ann Clin Transl Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000001098","article-title":"Clinical and laboratory features in anti-Nf155 autoimmune nodopathy","volume":"9","author":"Martin-Aguilar","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-rituximab antibody in patients with nmosds treated with low dose rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J Neuroimmunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211191","article-title":"Predicting and managing primary and secondary non-response to rituximab using b-cell biomarkers in systemic lupus erythematosus","volume":"76","author":"Md Yusof","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-017-3848-6","article-title":"Rituximab in clinical practice: Dosage, drug adherence, ig levels, infections, and drug antibodies","volume":"36","author":"Einarsson","year":"2017","journal-title":"Clin Rheumatol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14498","article-title":"Ocrelizumab in a case of refractory chronic inflammatory demyelinating polyneuropathy with anti-rituximab antibodies","volume":"27","author":"Casertano","year":"2020","journal-title":"Eur J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/ftira8","article-title":"Anti-rituximab antibodies affect pharmacokinetics and pharmacodynamics of rituximab in children with immune-mediated diseases","volume":"40","author":"Oomen","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2019","journal-title":"Front Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/s0140-6736(78)92022-6","article-title":"Steroids in acute polyneuropathy","volume":"2","author":"Hughes","year":"1978","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.54.3.615","article-title":"Distal acquired demyelinating symmetric neuropathy","volume":"54","author":"Katz","year":"2000","journal-title":"Neurology"},{"key":"B17","article-title":"Mechanism of action of rituximab","author":"Maloney","year":"2001","journal-title":"Anticancer Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the cdr regions","volume":"2","author":"Harding","year":"2010","journal-title":"mAbs"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1298473","article-title":"Immunogenicity of biotherapeutics: Causes and association with posttranslational modifications","volume":"2016","author":"Kuriakose","year":"2016","journal-title":"J Immunol Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0055","article-title":"Transient down-modulation of Cd20 by rituximab in patients with chronic lymphocytic leukemia","volume":"102","author":"Jilani","year":"2003","journal-title":"Blood"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.109041","article-title":"Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis","volume":"69","author":"Thurlings","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-020-04629-w","article-title":"Unfavorable impact of anti-rituximab antibodies on clinical outcomes in children with complicated steroid-dependent nephrotic syndrome","volume":"35","author":"Fujinaga","year":"2020","journal-title":"Pediatr Nephrol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517720044","article-title":"Rituximab in multiple sclerosis: Frequency and clinical relevance of anti-drug antibodies","volume":"24","author":"Dunn","year":"2018","journal-title":"Mult Scler"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2009.05.007","article-title":"Immunogenicity of rituximab in patients with severe pemphigus","volume":"132","author":"Schmidt","year":"2009","journal-title":"Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00467-021-05069-w","article-title":"Anti-rituximab antibodies in pediatric steroid-dependent nephrotic syndrome","volume":"37","author":"Bertrand","year":"2022","journal-title":"Pediatr Nephrol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez430","article-title":"Immunization to rituximab is more frequent in systemic autoimmune diseases than in rheumatoid arthritis: Ofatumumab as alternative therapy","volume":"59","author":"Combier","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences","volume":"155","author":"Saffari","year":"2022","journal-title":"Indian J Med Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"New Engl J Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.5812\/ijcm.64983","article-title":"Immunogenicity of rituximab, trastuzumab, and bevacizumab monoclonal antibodies in patients with malignant diseases","author":"Saffari","year":"2018","journal-title":"International Journal of Cancer Management"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I\/Ii dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis rheumatism"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralising capacity, associate with lower circulating drug levels and earlier relapse in lupus","author":"Wincup","year":"2022","journal-title":"Rheumatol (Oxford England)"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/jci124694","article-title":"Anti-Neurofascin-155 Igg4 antibodies prevent paranodal complex formation in vivo","volume":"129","author":"Manso","year":"2019","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1212\/nxi.0000000000001116","article-title":"Igg4-mediated neurologic autoimmunities: Understanding the pathogenicity of Igg4, ineffectiveness of ivig, and long-lasting benefits of anti-b cell therapies","volume":"9","author":"Dalakas","year":"2022","journal-title":"Neurology(R) neuroimmunology Neuroinflamm"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201948454","article-title":"Divergent chemokine receptor expression and the consequence for human Igg4 b cell responses","volume":"50","author":"Unger","year":"2020","journal-title":"Eur J Immunol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.939062","article-title":"Effect of low-dose rituximab treatment on autoimmune nodopathy with anti-contactin 1 antibody","volume":"13","author":"Hou","year":"2022","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s13075-021-02589-6","article-title":"First exposure to rituximab is associated to high rate of anti-drug antibodies in systemic lupus erythematosus but not in anca-associated vasculitis","volume":"23","author":"Faustini","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102251","article-title":"Treatment of mog-Igg-Associated disorder with rituximab: An international study of 121 patients","volume":"44","author":"Whittam","year":"2020","journal-title":"Multiple sclerosis related Disord"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2013.3071","article-title":"A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder","volume":"70","author":"Kim","year":"2013","journal-title":"JAMA Neurol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2021.01.022","article-title":"Analysis and management of rituximab resistance in Pla2r1-associated membranous nephropathy","volume":"6","author":"Teisseyre","year":"2021","journal-title":"Kidney Int Rep"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.665136","article-title":"Anti-neurofascin 155 antibody-positive chronic inflammatory demyelinating Polyneuropathy\/Combined central and peripheral demyelination: Strategies for diagnosis and treatment based on the disease mechanism","volume":"12","author":"Kira","year":"2021","journal-title":"Front Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121705\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T04:33:45Z","timestamp":1679978025000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1121705\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2023.1121705"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1121705","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"article-number":"1121705"}}